Are Toll-like receptors and decoy receptors involved in the immunopathogenesis of systemic lupus erythematosus and lupus-like syndromes? by Guggino, G. et al.
Hindawi Publishing Corporation
Clinical and Developmental Immunology
Volume 2012, Article ID 135932, 5 pages
doi:10.1155/2012/135932
Review Article
Are Toll-Like Receptors and Decoy Receptors Involved in
the Immunopathogenesis of Systemic Lupus Erythematosus and
Lupus-Like Syndromes?
Giuliana Guggino,1, 2 Anna Rita Giardina,2 Francesco Ciccia,2 Giovanni Triolo,2
Francesco Dieli,1 and Guido Sireci1
1Dipartimento di Biopatologia e Biotecnologie Mediche e Forensi, Universita` degli Studi di Palermo, DIBIMEF,
Corso Tukory 211, 90100 Palermo, Italy
2Divisione di Reumatologia, Dipartimento Biomedico di Medicina Interna e Specialistica, Universita` degli Studi di Palermo,
90133 Palermo, Italy
Correspondence should be addressed to Guido Sireci, guido.sireci@unipa.it
Received 30 April 2011; Revised 29 June 2011; Accepted 30 June 2011
Academic Editor: Anisur Rahman
Copyright © 2012 Giuliana Guggino et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
In this paper we focus our attention on the role of two families of receptors, Toll-like receptors (TLR) and decoy receptors (DcR)
involved in the generation of systemic lupus erythematosus (SLE) and lupus-like syndromes in human and mouse models. To
date, these molecules were described in several autoimmune disorders such as rheumatoid arthritis, antiphospholipids syndrome,
bowel inflammation, and SLE. Here, we summarize the findings of recent investigations on TLR and DcR and their role in the
immunopathogenesis of the SLE.
1. Introduction
Systemic lupus erythematosus (SLE) and lupus-like syn-
dromes are multiorgan autoimmune diseases whose patho-
genesis is multifactorial. Genetic and environmental factors,
together with abnormalities of both the innate and the
adaptive immune system, are involved. Although faulty
activation of autoreactive B lymphocytes and autoantibodies
is the hallmark of SLE, other cell subsets are involved in the
pathogenesis of the disease. In this context dendritic cells
(DC) or other antigen presenting cells (APC) as well as B and
T lymphocytes appear to be involved through the activation
of autoantibodies, the complement pathway, as well as
cytokines and chemokines which in turn activate diﬀerent
eﬀector mechanisms. Recently studies demonstrated an
important role of molecular mechanisms of innate immunity
in the cascade of events that contribute to the disease [1].
In this paper we focus our attention on the role of two
families of receptors such as TLR and DcR involved in the
generation of SLE and lupus-like syndromes in human and
mouse models.
2. Relevance of TLR in SLE and
Lupus-Like Syndromes
Toll-like receptors (TLR) are pattern recognition receptors
capable of recognizing specific pathogen-associated molec-
ular patterns (PAMPs) conserved among microorganisms as
a part of innate immune system. There are currently twelve
known TLR in mammals, which identify common con-
stituents of invading pathogens including double-stranded
and single-stranded RNA, unmethylated CpG DNA, bacte-
rial lipopolysaccharide (LPS), lipoproteins, and flagellin [2].
TLRs’ binding with several exogenous and/or endogenous
ligands activates numerous transcription factors including
activating protein-1 (AP-1), nuclear factor-κB (NF-κB), and
some of the interferon regulatory factors (IRFs) [3]. A num-
ber of adaptor molecules are involved in the TLR signaling
2 Clinical and Developmental Immunology
pathway, including myeloid diﬀerentiation primary response
gene 88 (MyD88), TIR domain-containing adaptor protein,
TIR domain-containing adapter inducing IFN-β (TRIF), and
TRIF-related adaptor molecule. TLR are expressed by a great
variety of cell types including professional immune cells, for
example, DC as well as nonprofessional immune cells, for
example, synovial fibroblast-like cells and epithelial cells [4,
5]. Their common theme, however, is to recognize infections
and to induce signaling pathways which ultimately lead to
the expression of inflammatory mediators and the induction
of an immune response. Innate signals were found to play
a crucial role in the development of autoimmune nephritis
[6]. Given the association between TLR and autoimmunity,
a great deal of work has been directed toward understanding
how these receptors act in disease progression. Studies
have shown two diﬀerent ways to describe the role of
TLR in autoimmune disease. The presence of exogenous
antigens, like viral ss-RNA, can stimulate TLR that can
activate resident immune cells to initiate and propagate
inflammation and autoimmunity, or the TLR can recognize
endogenous self-antigens and generate an aggressive autoim-
mune response in tissues. A crucial point in the generation
of autoimmune disease is represented by defective apoptotic
cell clearance, common among SLE patients, that can lead
to development of antinuclear antibodies [7]. A number of
studies have hypothesized that ineﬃcient clearance of apop-
totic debris triggers nucleic acid-binding TLR, which induce
the B-cell response and subsequent antinuclear antibodies
(ANA) production. Studies have demonstrated that as many
as one million cells die each second by apoptosis in the
human body as a part of normal tissue turnover, although,
usually, this phenomenon does not cause autoreactivity [8,
9]. In fact nuclear and cytoplasmic material is sequestered
and digested trough autophagy that constitutes an important
catabolic mechanism; therefore a failure in autophagy blocks
the removal of apoptotic bodies and influences the immuno-
genicity of death cells [9]. Moreover, if we consider that an
apoptotic cell contains a lot of modified self-antigens, the
connection between the clearance of apoptotic bodies and
autoreactive activation is quite plausible [8, 10, 11]. In 2006
Gaipl et al. demonstrated that an impaired clearance of dying
cells may explain accumulation of apoptotic cells in SLE
tissues contributing to the development of SLE in humans
and mice by several mechanisms [11]. Autoreactive B cells
in SLE internalize immune complexes or apoptotic material
containing nucleic acids that activate TLRs, causing increased
expression of the BAFF receptor TACI and increasing tissue
damage mediated by autoantibodies [12–14].
Recently, two TLR, namely, TLR7 and 9 have been con-
nected to both human and mouse models of SLE and lupus-
like syndromes where they act synergistically with BCR to
induce B-cell proliferation [3, 15, 16]. In addition, treatment
of lupus-prone mice with a dual inhibitor of TLR-7 and TLR-
9 leads to the reduction of autoantibody production and
amelioration of disease symptoms [17]. This consideration
suggests that aberrant activation of a number of TLR
pathways may lead to the initiation and/or perpetuation of
SLE. TLR7 and TLR9 blockers, such as antimalarials like
hydroxychloroquine, have been used to treat SLE for many
years because it can block activation of TLRs by inhibiting
endosome maturation. More recently other drugs have been
developed to activate or inhibit TLRs [3].
Experiments conducted in two diﬀerent murine strains
have demonstrated that injection of syngeneic late apoptotic
thymocytes into wild-type B6 mice led to anti-dsDNA
and antihistone antibody production whereas injection into
MyD88−/− mice had no eﬀect, suggesting that TLR stimula-
tion is important in development of anti-dsDNA antibodies
in situations of late apoptotic cell excess. The DNA-binding
TLR9 has also been heavily studied in connection with
murine lupus in MRLlpr/lpr strains. TLR9 deficiency in
some lupus models including MRLlpr/lpr mice can lead
to reductions or alterations in antichromatin antibodies;
however, TLR9 deficiency paradoxically leads to disease
exacerbation in many experimental models [15].
TLR7 has been shown to play an important role in
several mouse models of SLE [6, 17–19]. The interaction
between TLR7 and ligands directly activates DCs and B cells
supporting the expansion of eﬀector T and B lymphocytes
specific for autoantigens. In addition, TLR7 activation could
be involved in breaking peripheral tolerance mediated by
Tregs, important to generate protection against pathogenic
autoreactive immunity [18]. Furthermore, TLR7 activation
by exogenous and endogenous TLR7 ligands impairs Treg
generation and function. Hackl et al. demonstrated that TLR
ligands have diﬀerential eﬀects on Treg generation. TLR7
and similarly TLR9 ligands but not TLR4 ligand (e.g., LPS)
reduced de novo generation of Tregs from naı¨ve T cells. This
eﬀect appears to be mediated by IL-6 with a minor role for
IFN-γ and IL-4 in inhibiting Treg generation in the presence
of TLR7 ligand, which is in accordance with a recent report
describing the influence of Th1-/Th2-polarizing cytokines
on Treg diﬀerentiation [20]. IL-6 inhibits conversion of
naı¨ve T cells into Tregs and supports Th17 diﬀerentiation
[21–23]. Expression of RORγτ and IL-17 mRNA in FOXP3+
T cells generated in the presence of TLR7 ligand suggested
the possibility of a Th17 regulatory cells [24]. Tregs were
originally believed to be a stable Th-cell lineage but since
then, several studies have clearly shown that Foxp3 expres-
sion can be downregulated in subpopulations of natural as
well as induced Tregs allowing conversion into Th1, Th2,
or Th17 eﬀector cells under the influence of polarizing
cytokines in vitro and in inflammatory environments in vivo
[24]. In summary, TLR7-modified immunoregulation by
Tregs contributes to the breakdown of peripheral tolerance
and development of autoimmunity in SLE, where activation
of TLR7 by endogenous ligands was shown to play a role in
the pathogenesis. New therapeutic approaches for SLE and
lupus-like syndromes would be better directed on modifying
Foxp3 expression by interfering with TLR7 activation or by
blocking downstream eﬀector cytokines such as IL-6.
TLR4 is another TLR thought to be involved in the
pathogenesis of glomerulonephritis in SLE. LPS-mediated
immune responses are mediated through Toll-like receptor
4 (TLR4) on the target cells. Overexpression of TLR4
in mice has led to autoimmune glomerulonephritis and
lupus-like disease [25], suggesting that LPS-mediated
TLR4 signaling plays a pivotal role in lupus nephritis [26].
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TLR4 as well as the commensal flora has been shown to be
essential for the production of anti-dsDNA and the immune
complex-mediated glomerulonephritis in transgenic mice
expressing surface gp96 [25]. Lee et al. demonstrated that
the activations of immature APC and autoreactive B cells
in anti-dsDNA Tg mice by TLR4 signaling correlated with
an increase in production of IFN-γ, IL-10, and anti-dsDNA
production. Therefore, discovery and development of novel
TLR4 and LPS antagonists may be a new paradigm for the
therapy of SLE [26].
Various studies concerning autoimmune diseases in
lupus-prone mouse models and from genome-wide associa-
tion studies in human lupus patients and in vitro studies with
cells obtained from patients showed a correlation between
nucleic acid-binding TLR and the progression and severity of
lupus and other autoimmune diseases [27]. Although there
has not been a new drug approved for the treatment of
lupus, current investigation regarding the targeting of TLRs
and their downstream eﬀectors is promising and therefore
merits further investigation. The accumulation of evidence
pointing towards the involvement of TLRs in autoimmunity
has opened the door for potential therapeutic interventions
directed to modulate Toll-like receptors expression and their
signaling pathways [15].
3. Decoy Receptor Role in Humans and
Murine SLE-Like Models
Decoy receptors are “silent scavengers” of CC chemokines
and cytokines, which play a key role in damping inflam-
mation and tissue damage [28]. Decoy receptors recognize
certain inflammatory cytokines with high aﬃnity and speci-
ficity, but are structurally incapable of signaling or presenting
the agonist to signaling receptor complexes. They act as a
molecular trap for the agonist and for signaling receptor
components [29]. Inhibition of T cell death could modify
clonal shrinkage after clonal expansion during an immune
response, resulting in the survival of abnormal self cross-
reactive T cells and, potentially, autoimmune disease.
At present, the DcR6 receptor, expressed on endothelial
cells, hematopoietic stem cells (HSC), megakaryocytes, mast
cells, and DC, is the focus of intense investigation in
the field of inflammation since it binds many inflamma-
tory CC chemokines (CCL2, CCL3, CCL4, CCL5, CCL7,
CCL8, CCL11, CCL14, CCL22, and weakly CCL17), without
triggering any signals in target cells [28]. Interestingly,
although previous studies have always focused on the anti-
inflammatory role of DcR6 in relationship with its capacity
to scavenge circulating proinflammatory CC chemokines,
recent studies in experimental autoimmune encephalomyeli-
tis (EAE), a mouse model of multiple sclerosis, have sug-
gested that DcR6 functions may be diﬀerent and can change
depending on the setting of the inflammatory conditions.
In EAE models, DcR6-deficient mice showed a significantly
lower immune response with a reduced inflammatory leuko-
cyte infiltration in the spinal cord and, consequently, a
decreased demyelization [28].
Recent studies have focused their attention on another
decoy receptor: DcR3. It is a tumor necrosis factor receptor
family member and is a secreted protein that can enhance
cell survival by interfering with multiple apoptosis pathways.
It is a decoy receptor for the Fas ligand (FasL) and can inhibit
FasL-induced apoptosis.
DcR3 seems to function like the soluble Fas (sFas) in
terms of binding FasL and competing with membrane Fas.
Hyperproduction of DcR3may be involved in the acquisition
of autoimmunity (DcR3 and T-cell activation). In 2007
Han et al. demonstrated that DcR3 overexpression could
lead to a lupus-like syndrome [30]. Since then, several
reports have identified DcR3 as a possible parameter and
risk factor for SLE and that its elevated levels in serum
can contribute to enhancing T cells activation in SLE. SLE
patients showed significantly high serum level of DcR3, and
the mean serum DcR3 level was higher for those with active
disease (SLE disease activity index (SLEDAI) > 10) compared
with that in patients with inactive disease (SLEDAI < 10). In
addition soluble DcR3-Fc enhanced T-cell proliferation and
increased interleukin-2 (IL-2) and IFN-γ production via co-
stimulation of T cells in response to cell death. Moreover,
enhanced T-cell reactivity to DcR3-induced costimulation
was demonstrated in lymphocytes from patients with SLE,
suggesting that the elevated serum DcR3 may be associated
with enhanced T-cell activation in vivo. It is likely that
the DcR3-Fc-induced T-cell proliferation is via interaction
between DcR3 and LIGHT (the cognate receptor). Previous
studies have demonstrated that DcR3 could bind to LIGHT
and transducer costimulatory signals into both human and
murine T cells [31]. It is still not clear whether there is
any particular T-cell subset responding to DcR3-induced
costimulation, and what eﬀector function will develop after
triggering by DcR3.
Normal T cells express low levels of DcR3 [32], and
healthy individuals have near-background serum levels [33].
DcR3 expression is augmented in activated T cells [32],
thus probably represent a fine-tuning mechanism to balance
the need for clonal expansion and subsequent massive
activation-induced cell death of T cells. A dysfunction of
this balance due to failed AICD might lead to pathologic
consequences, such as autoimmune disease including SLE.
Studies conducted with DcR3 transgenic mice with actin
promoter-driven expression of human DcR3 demonstrated
these mice to manifest a lupus-like syndrome after 5-6
months of age, thus, suggesting that DcR could play a role
in the complex intertwinement of mechanism that drive the
pathogenesis of lupus-like syndromes. The hypothetical role
of decoy receptors in lupus-like syndromes could be diﬀerent
to that reported in experimental Mtb infection [34]; in
systemic autoimmune disease the increase of decoy receptors,
binding more chemokines, could amplify the recruitment
of activated cells (neutrophils, macrophages, lymphocytes,
dendritic cells, etc.) increasing the inflammatory state of the
tissue damaged by autoimmune reactions.
4. Concluding Remarks
The pathogenesis of SLE and lupus-like syndromes in
humans and mice is multifactorial. Several factors can
contribute to the immunopathogenesis of SLE and lupus-like
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Figure 1: Mechanisms involved in the pathogenesis of SLE and lupus-like syndromes. Diﬀerent cells and receptors contribute to the
activation of B cells secreting autoantibodies; these Immunoglobulins cause tissue damage.
syndromes (sex, age, hormones, infectious background,
environmental factors, drugs, abnormalities of both innate
and adaptive immune system). Here, we draw your attention
to two kinds of receptors associated with innate immunity as
players in the pathogenesis of SLE and lupus-like syndromes:
TLRs (7, 9, and 4) as possible receptors of autoantigenic
molecules and decoy receptors as molecules able to propa-
gate autoimmune inflammation acting in synergy to cause
autoimmune inflammations (Figure 1). Our paper, high-
lighting the new players in this autoimmune disorder, could
oﬀer the opportunity to design new immunotherapeutical
approaches for systemic autoimmune diseases.
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